Published summary: 2026-03-07
Where the evidence converges
Mega-analysis of 400 IV THC infusions found psychosis-like symptoms in 45% of healthy volunteers, with effects increasing with dose and decreasing with regular cannabis use history
Strong evidence · 13 studies
Intravenous THC administration does not replicate real-world cannabis use (smoking, edibles). Participants were healthy volunteers, not people at high risk for psychosis. The controlled setting may mo
Meta-analysis of 372 participants found THC's brain effects are dose-dependent and track with CB1 receptor density across regions
Strong evidence · 13 studies
Meta-analysis limited to studies using acute THC challenges under experimental conditions, which may not fully represent chronic use patterns. Individual variation in receptor density was not captured
Meta-analysis of 28 studies found blood and saliva THC levels are poor predictors of driving impairment, with negligible to weak correlations that disappear entirely in regular cannabis users
Strong evidence · 13 studies
Analyses in regular users were less robust due to fewer studies. Most studies used simulated rather than real-world driving.
Where questions remain
Data from 120 subjects showed cannabis tolerance develops and fades quickly, while withdrawal symptoms including insomnia, irritability, and tremor appeared after as few as 7 days of use
Moderate evidence · 49 studies
Data from controlled research settings may not reflect real-world usage patterns. The 120 subjects likely represented a relatively homogeneous population. Withdrawal was described as mild and transien
Review finding cannabis increases heart rate with rapid tolerance development, poses minimal risk for young healthy users but significant risks for people with existing cardiovascular disease
Moderate evidence · 49 studies
As a narrative review, the evidence was synthesized without systematic methodology. Most data came from studies in young, healthy subjects and may not apply to older or medically compromised populatio
Review of animal studies found cannabinoid tolerance develops through receptor down-regulation, withdrawal symptoms are generally milder than with other drugs, and tolerant animals showed no increased vulnerability to morphine
Moderate evidence · 49 studies
All evidence comes from animal models, which may not fully translate to human experience. The review notes that results have been controversial in various aspects. The pharmacokinetic differences betw
Controlled study of 23 marijuana users found varying CBC and CBD concentrations did not change the effects of smoked marijuana, confirming THC as the primary active ingredient
Moderate evidence · 49 studies
The CBD and CBC concentrations tested were relatively low compared to some cannabis preparations. The study used only two THC dose levels that may not have been different enough to detect dose-depende
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Meta-Analysis Confirms Cannabis Can Cause Paranoid Symptoms
Paranoia is common and has significant social consequences. This meta-analysis provides converging evidence from both experimental (causal) and observational designs that cannabis, particularly THC-dominant products, can cause paranoid symptoms.
Meta-Analysis Found CBD and THC Had Trivial Effects on Blood Inflammation Markers
CBD and THC are widely marketed as anti-inflammatory, often based on preclinical data. This meta-analysis of actual human clinical trials shows that the anti-inflammatory effects observed in cells and animals have not consistently translated to measurable changes in human blood markers.
Where THC acts in the brain depends on dose and how many cannabinoid receptors are present
Identifying where THC acts most strongly in the brain, and why, helps explain the wide range of cognitive effects reported by cannabis users and could inform dosing strategies for therapeutic applications.
Blood and Saliva THC Levels Are Poor Indicators of Driving Impairment
Many jurisdictions use blood or oral fluid THC levels to identify impaired drivers, similar to blood alcohol. This meta-analysis shows THC biomarkers are fundamentally different from blood alcohol as impairment indicators.
Mega-analysis of 400 THC infusions confirms THC induces psychosis-like symptoms in nearly half of healthy volunteers
This is the most comprehensive analysis of THC-induced psychosis-like effects in controlled settings, confirming the dose-dependent relationship and demonstrating that tolerance from regular use partially protects against these effects.
CBD pre-treatment made cannabis worse, not better, for people with schizophrenia
This directly challenges the popular assumption that CBD protects against THC's harmful effects, particularly in the most vulnerable population.
How the research developed
Pre-2000
3 studies published. Includes 1 RCTs.
2000–2009
12 studies published. Includes 3 RCTs, 3 strong-evidence studies.
2010–2014
22 studies published. Includes 7 RCTs.
2015–2019
52 studies published. Includes 12 RCTs, 5 strong-evidence studies.
2020–present
239 studies published. Includes 5 meta-analyses, 18 RCTs, 36 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 328 peer-reviewed studies: 5 meta-analyses (2%), 41 randomized controlled trials (13%), 90 observational studies (27%), 53 reviews (16%), 10 case studies (3%), 129 other study types (39%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.